{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:43:01Z","timestamp":1792028581242,"version":"4.4.0"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Evaluate the efficacy and safety of faricimab for treatment-na\u00efve and pre-treated diabetic macular oedema (DME) in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre, retrospective cohort study examined consecutive DME patients treated with faricimab for \u22651 year. Data were collected at predefined time points. Primary outcomes were mean changes in corrected visual acuity (VA), centre-point retinal thickness (CRT) and central subfield thickness (CST) and treatment intervals and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>184 eyes with DME were included: 61 (33.2%) were treatment-na\u00efve, and 123 (66.8%) were pretreated. In treatment-na\u00efve eyes, VA improved from 69.7\u00b115 Early Treatment of Diabetic Retinopathy Study letters at baseline to 73.9\u00b114.1 after 12\u2009months (p=0.014), while it remained stable in pretreated eyes (71.2\u00b114.2 vs 73.0\u00b112.9; p=0.14). CST decreased significantly in both groups (treatment-na\u00efve (366.1\u00b1108.3\u2009\u00b5m to 316.4\u00b1113.5\u2009\u00b5m, p&lt;0.001); pretreated (339.1\u00b193.1\u2009\u00b5m to 298.3\u00b165.8\u2009\u00b5m, p&lt;0.001)). Thirty-one percent of na\u00efve eyes and 21.1% of pretreated eyes were completely dry after 12\u2009months. In treatment-na\u00efve eyes, the mean treatment interval was 12.7\u00b16.4\u2009weeks at 12\u2009months. In pretreated eyes, the interval increased from 6.0\u00b13.0\u2009to 7.8\u00b13.6\u2009weeks (p&lt;0.001). Over 12\u2009months, 8.1\u00b12.1\u2009and 9.4\u00b12.5 injections were administered to na\u00efve and pretreated eyes, respectively (p&lt;0.001). Of the five recorded AEs, two cases of non-infectious intraocular inflammation and one cerebrovascular event were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Over 12\u2009months, faricimab demonstrated good efficacy and safety in both treatment-na\u00efve and pretreated eyes with DME. There was a reduction in CST and improved VA in treatment-na\u00efve eyes and stable VA in pretreated eyes. The low number of AEs supports a favourable risk-benefit profile of faricimab in a real-world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002467","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:15:13Z","timestamp":1769771713000},"page":"e002467","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report"],"prefix":"10.1136","volume":"11","author":[{"given":"Amr","family":"Saad","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Stadtspital Zurich Triemli, Z\u00fcrich, Switzerland"},{"name":"Spross Research Institute, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Plasencia","sequence":"additional","affiliation":[{"name":"Medical Retina & Clinical Research Department, Vista Klinik, Binningen, Switzerland"},{"name":"University of Basel Faculty of Medicine, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Garweg","sequence":"additional","affiliation":[{"name":"Berner Augenklinik am Lindenhofspital, Bern, Switzerland"},{"name":"Department of Ophthalmology, Inselspital University Hospital Bern, Bern, Switzerland"},{"name":"Swiss Eye Institute, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8752-8390","authenticated-orcid":false,"given":"Isabel Barbara","family":"Pfister","sequence":"additional","affiliation":[{"name":"Swiss Eye Institute, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion R","family":"Munk","sequence":"additional","affiliation":[{"name":"Ophthalmology, Inselspital, University Hospital Bern, Bern, Switzerland"},{"name":"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Augen\u00e4rztepraxisgemeinschaft Gutblick AG, Pf\u00e4ffikon, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maria","family":"Eandi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jules Gonin Eye Hospital, Lausanne, Switzerland"},{"name":"Department of Surgical Sciences, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine Anne","family":"Zweifel","sequence":"additional","affiliation":[{"name":"Universitatsspital Zurich Augenklinik und Poliklinik, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland, Lugano, Switzerland"},{"name":"Faculty of Biomedical Sciences, University of Southern Switzerland, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Bartolomeo","sequence":"additional","affiliation":[{"name":"Research Center, Swiss Visio Montchoisi, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stillenmunkes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Inselspital University Hospital Bern, Bern, Switzerland"},{"name":"Augen\u00e4rztepraxisgemeinschaft Gutblick AG, Pf\u00e4ffikon, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Schild","sequence":"additional","affiliation":[{"name":"Swiss Eye Institute, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jules Gonin Eye Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Gabathuler","sequence":"additional","affiliation":[{"name":"Universitatsspital Zurich Augenklinik und Poliklinik, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno","family":"Menghini","sequence":"additional","affiliation":[{"name":"Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland, Lugano, Switzerland"},{"name":"Faculty of Biomedical Sciences, University of Southern Switzerland, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Ambersin","sequence":"additional","affiliation":[{"name":"Research Center, Swiss Visio Montchoisi, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Froehlich","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Artemiev","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kantonsspital St Gallen, St. Gallen, Switzerland"},{"name":"University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Weinberger","sequence":"additional","affiliation":[{"name":"Pallas Kliniken AG, Olten, Switzerland"},{"name":"Department of Ophthalmology, RWTH Aachen University, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Stadtspital Zurich Triemli, Z\u00fcrich, Switzerland"},{"name":"Spross Research Institute, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor Mark","family":"Somfai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Stadtspital Zurich Triemli, Z\u00fcrich, Switzerland"},{"name":"Spross Research Institute, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-0310","authenticated-orcid":false,"given":"Katja","family":"Hatz","sequence":"additional","affiliation":[{"name":"Medical Retina & Clinical Research Department, Vista Klinik, Binningen, Switzerland"},{"name":"University of Basel Faculty of Medicine, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026090204250874000_11.1.e002467.1","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2156273","article-title":"Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory","volume":"2016","author":"Romero-Aroca","year":"2016","journal-title":"J Diabetes Res"},{"key":"2026090204250874000_11.1.e002467.2","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-015-0026-2"},{"key":"2026090204250874000_11.1.e002467.3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"The Lancet"},{"key":"2026090204250874000_11.1.e002467.4","unstructured":"National Institute for Health and Care Excellence . Diabetic retinopathy: management and monitoring. 2023."},{"key":"2026090204250874000_11.1.e002467.5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41433-023-02667-w","article-title":"Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients","volume":"38","author":"Rennie","year":"2024","journal-title":"Eye (Lond)"},{"key":"2026090204250874000_11.1.e002467.6","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910666","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"11","author":"Regula","year":"2019","journal-title":"EMBO Mol Med"},{"key":"2026090204250874000_11.1.e002467.7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"The Lancet"},{"key":"2026090204250874000_11.1.e002467.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.026"},{"key":"2026090204250874000_11.1.e002467.9","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051416","article-title":"Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose","volume":"15","author":"Veritti","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026090204250874000_11.1.e002467.10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s40123-024-00925-y","article-title":"Enhancing Diabetic Macular Edema Treatment Outcomes: Exploring the ESASO Classification and Structural OCT Biomarkers","volume":"13","author":"Panozzo","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"2026090204250874000_11.1.e002467.11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.2350"},{"key":"2026090204250874000_11.1.e002467.12","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d87e04"},{"key":"2026090204250874000_11.1.e002467.13","doi-asserted-by":"crossref","DOI":"10.1186\/s40942-024-00566-0","article-title":"Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review","volume":"10","author":"Nasimi","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"2026090204250874000_11.1.e002467.14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1167\/iovs.65.14.46","article-title":"Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema","volume":"65","author":"Huber","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026090204250874000_11.1.e002467.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.06.047"},{"key":"2026090204250874000_11.1.e002467.16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm13102778","article-title":"Beyond VEGF: Angiopoietin-Tie Signaling Pathway in Diabetic Retinopathy","volume":"13","author":"Chen-Li","year":"2024","journal-title":"J Clin Med"},{"key":"2026090204250874000_11.1.e002467.17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","article-title":"Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases","volume":"30","author":"Nicol\u00f2","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"2026090204250874000_11.1.e002467.18","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S424314"},{"key":"2026090204250874000_11.1.e002467.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.01.039"},{"key":"2026090204250874000_11.1.e002467.20","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.2147\/DDDT.S427416","article-title":"Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies","volume":"17","author":"Panos","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"2026090204250874000_11.1.e002467.21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"2026090204250874000_11.1.e002467.22","first-page":"639","article-title":"Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema","volume":"12","author":"Garweg","year":"2023","journal-title":"Ophthalmology and Diabetology Treatment Aspects Ophthalmology and Therapy"},{"key":"2026090204250874000_11.1.e002467.23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10050981","article-title":"Inflammatory Complications of Intravitreal Anti-VEGF Injections","volume":"10","author":"Cox","year":"2021","journal-title":"J Clin Med"},{"key":"2026090204250874000_11.1.e002467.24","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1192464","article-title":"Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion","volume":"17","author":"Canonica","year":"2023","journal-title":"Front Cell Neurosci"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:25:26Z","timestamp":1788348326000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,30]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjophth-2025-002467"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002467","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}